IRIS
BERARDI, Rossana
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 33.328
EU - Europa 14.599
AS - Asia 12.251
SA - Sud America 2.913
Continente sconosciuto - Info sul continente non disponibili 1.158
AF - Africa 743
OC - Oceania 22
Totale 65.014
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 32.338
RU - Federazione Russa 4.174
SG - Singapore 4.013
IT - Italia 2.747
VN - Vietnam 2.461
BR - Brasile 2.289
CN - Cina 1.976
UA - Ucraina 1.363
HK - Hong Kong 1.296
DE - Germania 1.197
IE - Irlanda 1.081
SE - Svezia 848
FR - Francia 734
FI - Finlandia 661
TR - Turchia 587
GB - Regno Unito 554
CA - Canada 460
DK - Danimarca 457
IN - India 392
BD - Bangladesh 354
CI - Costa d'Avorio 305
KR - Corea 272
AR - Argentina 236
NL - Olanda 172
MX - Messico 151
PL - Polonia 140
JP - Giappone 133
ZA - Sudafrica 123
MA - Marocco 116
ID - Indonesia 110
IQ - Iraq 109
EC - Ecuador 102
CO - Colombia 89
LT - Lituania 89
PK - Pakistan 79
CR - Costa Rica 71
ES - Italia 71
BE - Belgio 70
AT - Austria 63
IL - Israele 55
UZ - Uzbekistan 54
HN - Honduras 50
PH - Filippine 50
CL - Cile 48
VE - Venezuela 48
SV - El Salvador 40
GT - Guatemala 39
PY - Paraguay 39
PR - Porto Rico 35
JM - Giamaica 32
KE - Kenya 32
NI - Nicaragua 31
RO - Romania 31
SA - Arabia Saudita 31
TN - Tunisia 31
TT - Trinidad e Tobago 31
AZ - Azerbaigian 30
MY - Malesia 30
PE - Perù 30
CW - ???statistics.table.value.countryCode.CW??? 29
EG - Egitto 28
SC - Seychelles 27
JO - Giordania 26
AE - Emirati Arabi Uniti 25
DZ - Algeria 25
KZ - Kazakistan 24
GP - Guadalupe 22
NP - Nepal 20
CZ - Repubblica Ceca 19
UY - Uruguay 19
TH - Thailandia 17
AU - Australia 14
SK - Slovacchia (Repubblica Slovacca) 14
TW - Taiwan 14
EU - Europa 13
AL - Albania 12
KG - Kirghizistan 12
CH - Svizzera 11
PS - Palestinian Territory 10
PT - Portogallo 10
RS - Serbia 10
BG - Bulgaria 9
BH - Bahrain 9
BO - Bolivia 9
BY - Bielorussia 9
DO - Repubblica Dominicana 9
ET - Etiopia 9
LB - Libano 9
GR - Grecia 8
NZ - Nuova Zelanda 8
SN - Senegal 8
NG - Nigeria 7
SI - Slovenia 7
AM - Armenia 6
BA - Bosnia-Erzegovina 6
HR - Croazia 6
IR - Iran 6
KW - Kuwait 6
LY - Libia 6
OM - Oman 6
Totale 63.794
Salva come PNG Salva come JPEG
Città #
Ashburn 5.624
Dallas 2.600
Singapore 2.593
Chandler 2.049
San Jose 1.517
Jacksonville 1.513
Fairfield 1.488
Council Bluffs 1.383
Hong Kong 1.250
Des Moines 1.181
Dublin 1.071
Boardman 1.004
New York 833
Ho Chi Minh City 784
Wilmington 738
Woodbridge 660
Seattle 658
Houston 621
Hanoi 568
The Dalles 523
Los Angeles 515
Ann Arbor 495
Beijing 492
Cambridge 480
Princeton 427
Lauterbourg 416
Lawrence 388
Munich 367
San Mateo 364
Moscow 343
Abidjan 305
Helsinki 288
Santa Clara 267
Milan 257
Hefei 231
São Paulo 231
Centro 217
Buffalo 198
Phoenix 192
Rome 192
Chicago 187
San Diego 187
London 148
Turin 140
Turku 137
Da Nang 132
Orem 130
Ancona 123
Warsaw 122
Haiphong 119
Washington 114
Montreal 109
Pune 106
Tokyo 104
Chennai 82
Brooklyn 80
Atlanta 79
Rio de Janeiro 79
Denver 72
Johannesburg 71
Frankfurt am Main 70
Guangzhou 70
Shanghai 70
Vilnius 68
Brussels 65
Nuremberg 62
Vancouver 62
Elk Grove Village 59
Toronto 59
Naples 58
Columbus 57
Poplar 53
Mexico City 52
Miano 52
Irving 51
Belo Horizonte 50
Salt Lake City 50
San Francisco 50
Boston 49
Hải Dương 49
Stockholm 47
Tashkent 46
San José 45
Amsterdam 44
Manchester 42
Baghdad 41
Marche 41
Brasília 40
Falls Church 40
Biên Hòa 39
Norwalk 38
San Salvador 36
Mumbai 35
Curitiba 34
Quito 34
Wuhan 34
Dhaka 33
Lynnwood 33
Porto Alegre 33
Bologna 31
Totale 39.566
Salva come PNG Salva come JPEG
Nome #
[11C]-Methionine Positron Emission Tomography in the Postoperative Imaging and Followup of Patients with Primary and Recurrent Gliomas 2.308
Contrasting Digital Fake News in Health: an Interdisciplinary Approach 842
Contrasting Fake News in Oncology: The First Declaration of Good Communication 824
The Role of Hyponatraemia Before Surgery in Patients With Radical Resected Pancreatic Cancer 290
A case report of metastatic giant sarcomatoid melanoma with BRAF V600E mutation: a complete response to targeted therapy 287
Metabolic phenotype of bladder cancer 273
Electrolyte disorders in advanced non-small cell lung cancer patients treated with immune check-point inhibitors: a systematic review and meta-analysis 267
Endometriosis-associated Clear Cell Carcinoma of the Abdominal Wall After Caesarean Section: A Case Report and Review of the Literature 253
Questioning the prognostic role of BAP-1 immunohistochemistry in malignant pleural mesothelioma: A single center experience with systematic review and meta-analysis 238
Impact of Signet-Ring Cell Histology in the Management of Patients with Non-Metastatic Gastric Cancer: Results from a Retrospective Multicenter Analysis Comparing FLOT Perioperative Chemotherapy vs. Surgery Followed by Adjuvant Chemotherapy 233
Anemia may influence the outcome of patients undergoing neoadjuvant treatment for rectal cancer 233
The role of 5-fluorouracil (5-FU) reintroduction with irinotecan or oxaliplatin in truly 5-FU-refractory advanced colorectal cancer patients. 229
Prognostic relevance of programmed cell death protein 1/programmed death-ligand 1 pathway in thymic malignancies with combined immunohistochemical and biomolecular approach 223
Clinical impact of different exosomes’ protein expression in pancreatic ductal carcinoma patients treated with standard first line palliative chemotherapy 215
Impact of polypharmacy for chronic ailments in colon cancer patients: A review focused on drug repurposing. 214
Extended efficacy and safety Denosumab in breast cancer patients with bone metastases not receiving prior bisphosphonate therapy. 214
Adjuvant treatment with Capecitabine in patients who received orthotopic liver transplantation with incidental diagnosis of intrahepatic cholangiocarcinoma. Implications on DPYD polymorphisms assessment: report of two cases and review of the literature 212
Are liver nested stromal epithelial tumors always low aggressive? 212
BRCA-associated protein 1 (BAP1) and miR-31 combination predicts outcomes in epithelioid malignant pleural mesothelioma 209
Impact of VEGF, VEGFR, PDGFR, HIF and ERCC1 gene polymorphisms on thymic malignancies outcome after thymectomy 208
The role of Aspirin as antitumoral agent for heavily pre-treated metastatic colorectal cancer patients receiving capecitabine monotherapy. BMC Cancer 208
Bone metastases in patients with metastatic renal cell carcinoma: Are they always associated with poor prognosis? 207
A germline missense mutation in exon 3 of the MSH2 gene in a Lynch syndrome family: correlation with phenotype and localization assay 207
1621P miRNA signature as early predictor of hyponatremia and survival in lung cancer: Preliminary results from the ISA retrospective study 206
85P NSCLC-Pro ClustAI: A machine learning model to prognostically stratify patients with advanced NSCLC treated with immune checkpoint inhibitors 204
Role of DCE-MR in predicting breast cancer subtypes. 204
The role of HER-3 expression in the prediction of clinical outcome for advanced colorectal cancer patients receiving irinotecan and cetuximab. 201
Optimal management of resected gastric cancer 197
Modifications of taste sensitivity in cancer patients: a method for the evaluations of dysgeusia 197
A novel approach to manage skin toxicity caused by therapeutic agents targeting epidermal growth factor receptor. 196
The prognostic and predictive role of hyponatremia in patients with advanced non-small cell lung cancer (NSCLC) with bone metastases 196
A classification prognostic score to predict OS in stage IV well-differentiated neuroendocrine tumors 196
Syndrome of inappropriate antidiuretic hormone secretion (Siadh): Optimal management 192
Beyond Microsatellite Instability: Evolving Strategies Integrating Immunotherapy for Microsatellite Stable Colorectal Cancer 192
A phase II study of neoadjuvant bevacizumab plus capecitabine and concomitant radiotherapy in patients with locally advanced rectal cancer. 191
Long‑responders to anti‑HER2 therapies: A case report and review of the literature 183
A multi-centre retrospective review of second-line therapy in advanced pancreatic adenocarcinoma. 182
5-Fluorouracil pharmacogenomics: still rocking after all these years? 182
Developments in the management of advanced soft-tissue sarcoma –€“ Olaratumab in context 182
A cost-benefit analysis of chemotherapy for gastric cancer. 180
Prospective observational study of taste assay in patients with solid tumors treated with standard chemotherapy (POTATO) 180
Body Mass Index and Hormone Receptor Status Influence Recurrence Risk in HER2-Positive Early Breast Cancer Patients 178
Therapeutic Potential of Tisotumab Vedotin in the Treatment of Recurrent or Metastatic Cervical Cancer: A Short Report on the Emerging Data 177
Nuclear factor-κB predicts outcome in locally advanced rectal cancer patients receiving neoadjuvant radio-chemotherapy. 177
Acute Peripheral Motor Neuropathy Induced by Oxaliplatin-Correlated Hypokalaemia 177
COVID-19 in breast cancer patients: a subanalysis of the OnCovid registry 177
Androgen receptor expression in early triple-negative breast cancer: clinical significance and prognostic associations. 176
The role of an immune checkpoint score in resected non-small cell lung cancer patients' prognosis 176
COVID-19 in patients with thoracic malignancies (TERAVOLT): first results of an international, registry-based, cohort study 176
Hyponatremia normalization as an independent prognostic factor in patients with advanced non-small cell lung cancer treated with first-line therapy 176
Pre-treatment neutrophil to lymphocyte ratio may be a useful tool in predicting survival in early triple negative breast cancer patients 175
Scientia Potentia Est: How the Italian World of Oncology Changes in the COVID-19 Pandemic 175
Predictive and prognostic role of E-cadherin protein expression in patients with advanced gastric carcinomas treated with palliative chemotherapy. 174
The impact of lifestyle interventions in high‐risk early breast cancer patients: A modeling approach from a single institution experience 174
Thymic neoplasms: an update on the use of chemotherapy and new targeted therapies. A literature review. 173
Pre-treatment systemic immune-inflammation represents a prognostic factor in patients with advanced non-small cell lung cancer 173
Electrolyte disorders in cancer patients: a systematic review 172
Role of DCE-MR imaging of the breast in predicting breast cancer subtypes: where are we going? 171
Lynphatic, blood vessel and perineural invasion identifies early-stage high-risk radically resected gastric cancer patients. 171
Gender Differences and Outcomes in Melanoma Patients 170
The Gustave Roussy Immune (GRIm)-Score Variation Is an Early-on-Treatment Biomarker of Outcome in Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Treated with First-Line Pembrolizumab 170
An observational retrospective analysis of the main metastatic site and corresponding locoregional treatment as a prognostic factor in metastatic gastric cancer 170
Benefits and limitations of a multidisciplinary approach in cancer patient management 169
Weighing the prognostic role of hyponatremia in hospitalized patients with metastatic solid tumors: the HYPNOSIS study 168
Correlations Between the Immune-related Adverse Events Spectrum and Efficacy of Anti-PD1 Immunotherapy in NSCLC Patients 168
Squamous cell carcinoma of the lung: clinical criteria for treatment strategy 165
A multicenter study of body mass index in cancer patients treated with anti-PD-1/PD-L1 immune checkpoint inhibitors: When overweight becomes favorable 165
Tumor burden as possible biomarker of outcome in advanced NSCLC patients treated with immunotherapy: a single center, retrospective, real-world analysis 165
Adjuvant treatment after surgical resection 165
Randomized active-controlled phase 2 study of Denosumab efficacy and safety in patients with breast cancer-related bone metastases. 164
Hyponatremia is a Predictor of Clinical Outcome for Resected Biliary Tract Cancers: A Retrospective Single-Center Study 163
Seminoma Retroperitoneal Relapse 23 Years After Surgery 163
PD-1 blockade therapy in renal cell carcinoma: current studies and future promises 161
Clinical and pathologic predictors of clinical outcome of malignant pleural mesothelioma 161
Incidence and risk of cardiotoxicity in cancer patients treated with targeted therapies 161
Medical treatment for cholangiocarcinoma 161
Managing hyponatremia in lung cancer: latest evidence and clinical implications 160
Expression Profiling of Circulating Tumor Cells in Pancreatic Ductal Adenocarcinoma Patients: Biomarkers Predicting Overall Survival 160
High CTLA-4 expression correlates with poor prognosis in thymoma patients 160
High-intensity statins are associated with improved clinical activity of PD-1 inhibitors in malignant pleural mesothelioma and advanced non-small cell lung cancer patients 160
Phase II study of pharmacogenetic-tailored therapy in elderly colorectal cancer patients. 159
Hyponatremia is a predictor of hospital length and cost of stay and outcome in cancer patients. 159
Adjuvant capecitabine in triple negative breast cancer patients with residual disease after neoadjuvant treatment: real-world evidence from CaRe, a multicentric, observational study 159
Cancer in Transgender and Gender-Diverse Persons: A Review 157
The Impact and Performance of the Molecular Tumor Board: Three-Year Activity in Precision Medicine for Treatment of Patients with Cancer from the Marche Region, in Italy 157
The role of angiogenetic single-nucleotide polymorphisms in thymic malignancies and thymic benign lesions 157
Hemoglobin and Neutrophil Count as Prognostic Factors in Cholangiocarcinoma Patients in 2nd Line Treatment Setting: Results from a Small Monocentric Retrospective Study 156
Irinotecan-Induced Transient Dysarthria: Case Series and Updated Literature Review 156
Systemic treatment for lung carcinoids: from bench to bedside 156
A multicenter, randomized, phase II/III study of dendritic cells loaded with allogeneic tumor cell lysate (MesoPher) in subjects with mesothelioma as maintenance therapy after chemotherapy: DENdritic cell Immunotherapy for Mesothelioma (DENIM) trial 156
Another side of the association between body mass index (BMI) and clinical outcomes of cancer patients receiving programmed cell death protein-1 (PD-1)/ Programmed cell death-ligand 1 (PD-L1) checkpoint inhibitors: A multicentre analysis of immune-related adverse events 156
A phase 1b study of the MET inhibitor capmatinib combined with cetuximab in patients with MET-positive colorectal cancer who had progressed following anti-EGFR monoclonal antibody treatment 155
Tumor-infiltrating lymphocytes and molecular response after neoadjuvant therapy for HR+/HER2− breast cancer: results from two prospective trials 155
Thymic Malignancies in the targeted terapies era 154
Gastrointestinal neuroendocrine tumors: Searching the optimal treatment strategy-A literature review 154
Impact of phosphoinositide-3-kinase and vitamin D3 nuclear receptor single-nucleotide polymorphisms on the outcome of malignant melanoma patients 154
Late immune-related adverse events in long-term responders to PD-1/PD-L1 checkpoint inhibitors: A multicentre study 154
Phosphorylated mTOR is associated to androgen receptor expression in early triple-negative breast cancer 154
Alarming Drop in Early Stage Colorectal Cancer Diagnoses After COVID-19 Outbreak: A Real-World Analysis from the Italian COVID-DELAY Study 153
NSCLC-Pro ClustAI: A Machine Learning Model to prognostically stratify patients with advanced NSCLC treated with immune checkpoint inhibitors 153
Totale 21.778
Salva come PNG Salva come JPEG
Categoria #
all - tutte 288.621
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 288.621
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/20222.068 0 0 0 0 42 224 124 209 303 207 328 631
2022/20236.355 518 648 404 531 338 1.618 2 325 1.357 58 411 145
2023/20243.659 580 83 234 408 574 877 52 132 10 131 51 527
2024/20258.278 851 754 371 158 339 357 692 323 1.948 658 824 1.003
2025/202626.712 1.508 1.944 2.531 2.583 2.424 1.579 4.136 2.244 3.946 1.974 826 1.017
2026/20276.508 1.111 1.199 1.054 2.624 520 0 0 0 0 0 0 0
Totale 65.014